The state of oral GLP-1s
One oral GLP-1 exists today: Rybelsus, with modest efficacy and burdensome food restrictions. Two oral GLP-1s are in Phase 3 or Phase 2 with far better profiles. The oral GLP-1 landscape will look completely different by 2028.
For patients who want the metabolic benefits of GLP-1 medications without weekly injections, the honest answer today is: the options are limited, but the pipeline is extraordinarily promising. This guide maps where oral GLP-1 therapy is now, what's coming, and what the clinical distinctions between each drug actually are.
What's Available Today: Rybelsus
Rybelsus (oral semaglutide) is the only FDA-approved oral GLP-1. It's approved for type 2 diabetes — not obesity. Weight loss in clinical trials averaged 5-8%, substantially below the injectable semaglutide that Wegovy delivers (~15%). Its limitations are inherent in how it works.
Rybelsus contains the same semaglutide as Ozempic, but semaglutide is a large peptide — your digestive system normally degrades it before absorption. Novo Nordisk solved this partially using SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), a penetration enhancer, but even with it, oral bioavailability is only ~1% under ideal conditions. Ideal conditions require: taking it on an empty stomach, waiting 30 minutes before eating or drinking anything other than 4 oz of water, and swallowing with minimal liquid. Real-world adherence to this protocol is poor, and weight loss results reflect it.
| Rybelsus | Orforglipron (Phase 3) | Amycretin (Phase 2) | |
|---|---|---|---|
| Type | Peptide (semaglutide) | Non-peptide small molecule | Unimolecular dual agonist |
| Food restrictions | Strict fasting required | None | None (oral) |
| Avg weight loss | ~5-8% | ~14.7% (Phase 2) | ~13.1% (Phase 1, 12 wk) |
| Approved for obesity | No | No (Phase 3) | No (Phase 2) |
| Available | Yes | 2026-2027 est. | 2029-2030 est. |
Orforglipron: The First True Oral GLP-1
Orforglipron (Eli Lilly) is a non-peptide small molecule GLP-1 receptor agonist. Its small molecule architecture means it doesn't require special absorption conditions — it can be taken with or without food, at any time of day. Phase 2 data showed 14.7% average weight loss at 36 weeks, comparable to injectable semaglutide in trials of similar duration. Phase 3 ATTAIN results are expected in 2025-2026.
Injectable GLP-1s are available now for those who qualify. Find options in your state.
Get My Match →Amycretin: The Next Oral Frontier
Amycretin (Novo Nordisk) is a unimolecular GLP-1/amylin co-agonist — a single molecule designed to activate both GLP-1 and amylin receptors simultaneously. Phase 1 tablet data showed 13.1% weight loss in just 12 weeks, an extraordinary early signal for such a short duration. Phase 2 is underway. Approval before 2029-2030 is unlikely.
The amylin pathway is distinct from GLP-1 — amylin is released with insulin and acts on different brain circuits. Combining them in one oral molecule, if it holds up in larger trials, could represent a significant advance over single-pathway oral options.
What This Means for Patients Who Want an Oral Option
If you want oral GLP-1 therapy right now: Rybelsus is available but has significant limitations and is only approved for diabetes. If you have type 2 diabetes and prefer oral medication, discuss Rybelsus with your provider. If you're primarily seeking weight loss, injectable semaglutide or tirzepatide will be more effective with today's options.
If you're willing to wait 1-2 years: orforglipron may offer an oral option with comparable efficacy to injectable semaglutide, without Rybelsus's inconvenience. This is worth tracking closely.
Read about orforglipron specifically, amycretin, or return to the future GLP-1 hub.
Frequently Asked Questions
Why is Rybelsus less effective than Ozempic?
Both contain semaglutide, but Rybelsus's oral bioavailability is only ~1% even under ideal conditions — compared to nearly complete bioavailability with injection. Less drug reaches the bloodstream, producing less effect.
Will orforglipron be as effective as Wegovy?
Phase 2 data suggests comparable efficacy (~15% weight loss) without the food restrictions. Phase 3 will be more definitive. The advantage is convenience, not necessarily greater efficacy.
What is the difference between orforglipron and amycretin?
Orforglipron activates the GLP-1 receptor only (same target as semaglutide) but as a small molecule. Amycretin activates both GLP-1 and amylin receptors in a single molecule — a more ambitious dual-pathway approach.
Ready to find your match?
Answer 5 quick questions and see licensed GLP-1 programs available in your state — matched to your budget. Free. No obligation.
Get My Match — Free →